Cover Image
市場調查報告書

弓蟲症:開發中產品分析

Toxoplasmosis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 302504
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
弓蟲症:開發中產品分析 Toxoplasmosis - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 32 Pages
簡介

所謂弓蟲症是因感染弓蟲症寄生蟲而引發的疾病。主要的症狀有身體疼痛、淋巴結朣、頭痛、發燒、倦怠感等。主要致病風險要素有HIV/AIDS及化療、免疫抑制劑等。主要的治療方法有抗瘧疾藥和抗生素等。

本報告提供全球各國的弓蟲症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

弓蟲症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

弓蟲症:企業正在開發的治療藥

弓蟲症:大學/機關研究中的治療藥

弓蟲症:開發中產品概況

  • 初期階段的產品

弓蟲症:企業開發中的產品

弓蟲症:大學/機關研究中的產品

弓蟲症的治療藥開發作的企業

Turing Pharmaceuticals AG

弓蟲症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各分子類型

藥物簡介

弓蟲症:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8210IDB

Summary

Global Markets Direct's, 'Toxoplasmosis - Pipeline Review, H1 2016', provides an overview of the Toxoplasmosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Toxoplasmosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Toxoplasmosis
  • The report reviews pipeline therapeutics for Toxoplasmosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Toxoplasmosis therapeutics and enlists all their major and minor projects
  • The report assesses Toxoplasmosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Toxoplasmosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Toxoplasmosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toxoplasmosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toxoplasmosis Overview
  • Therapeutics Development
    • Pipeline Products for Toxoplasmosis - Overview
    • Pipeline Products for Toxoplasmosis - Comparative Analysis
  • Toxoplasmosis - Therapeutics under Development by Companies
  • Toxoplasmosis - Therapeutics under Investigation by Universities/Institutes
  • Toxoplasmosis - Pipeline Products Glance
    • Early Stage Products
  • Toxoplasmosis - Products under Development by Companies
  • Toxoplasmosis - Products under Investigation by Universities/Institutes
  • Toxoplasmosis - Companies Involved in Therapeutics Development
    • Turing Pharmaceuticals AG
  • Toxoplasmosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Drug Profiles
    • Monoclonal Antibody for Toxoplasmosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Polysaccharide for Oncology, Infectious Disease and Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Toxoplasmosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRP-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Toxoplasmosis - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Toxoplasmosis, H1 2016
  • Number of Products under Development for Toxoplasmosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Toxoplasmosis - Pipeline by Turing Pharmaceuticals AG , H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Toxoplasmosis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Toxoplasmosis, H1 2016
  • Number of Products under Development for Toxoplasmosis - Comparative Analysis, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top